Forest Laboratories, Inc. Announces Health Canada Approval of BYSTOLIC for the Treatment of Hypertension

  Forest Laboratories, Inc. Announces Health Canada Approval of BYSTOLIC for   the Treatment of Hypertension  Business Wire  NEW YORK -- January 17, 2013  Forest Laboratories, Inc. (NYSE:FRX) announced today that its Canadian subsidiary, Forest Laboratories Canada Inc. has received a Notice of Compliance from Health Canada for BYSTOLIC® (nebivolol) tablets, a once daily beta blocker for the treatment of hypertension.  “We are pleased that Health Canada has granted approval for BYSTOLIC. This is an important milestone for Forest, as it is the first product approved for our newly established Canadian subsidiary. We look forward to bringing additional innovative Forest products to the Canadian market,” commented David Solomon, Senior Vice President of Corporate Development and Strategic Planning, Forest Laboratories, Inc.  BYSTOLIC is expected to be available to Canadian patients in Q2 2013.  Forest Laboratories Canada Inc. operations are based in Toronto, Ontario. To learn more, visit www.frx.ca.  About Forest Laboratories, Inc.  Forest Laboratories' (NYSE: FRX) longstanding global partnerships and track record developing and marketing pharmaceutical products in the United States have yielded its well-established central nervous system and cardiovascular franchises and innovations in anti-infective, respiratory, gastrointestinal and pain management medicine. Forest’s pipeline, the most robust in its history, includes product candidates in all stages of development across a wide range of therapeutic areas. The Company is headquartered in New York, NY. To learn more, visit www.FRX.com.  Except for the historical information contained herein, this release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including the difficulty of predicting FDA approvals, the acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, the timely development and launch of new products, and the risk factors listed from time to time in Forest Laboratories' Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and any subsequent SEC filings. Forest assumes no obligation to update forward-looking statements contained in this release to reflect new information or future events or developments.  Contact:  Forest Laboratories, Inc. Frank J. Murdolo, 212-224-6714 Vice President - Investor Relations media.relations@frx.com  
Press spacebar to pause and continue. Press esc to stop.